{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T01:51:28Z","timestamp":1780451488523,"version":"3.54.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T00:00:00Z","timestamp":1699488000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T00:00:00Z","timestamp":1699488000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100015371","name":"Recor Medical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015371","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Universit\u00e4tsklinikum des Saarlandes und Medizinische Fakult\u00e4t der Universit\u00e4t des Saarlandes"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n              <jats:title>Background<\/jats:title>\n              <jats:p>Hypertension is a major public health issue due to its association with cardiovascular disease risk. Despite the availability of effective antihypertensive drugs, rates of blood pressure (BP) control remain suboptimal. Renal denervation (RDN) has emerged as an effective non-pharmacological, device-based treatment option for patients with hypertension. The multicenter, single-arm, observational Global Paradise\u2122 System (GPS) registry has been designed to examine the long-term safety and effectiveness of ultrasound RDN (uRDN) with the Paradise System in a large population of patients with hypertension.<\/jats:p>\n            <\/jats:sec><jats:sec>\n              <jats:title>Methods<\/jats:title>\n              <jats:p>The study aims to enroll up to 3000 patients undergoing uRDN in routine clinical practice. Patients will be recruited over a 4-year period and followed for 5\u00a0years (at 3, 6, and 12\u00a0months after the uRDN procedure and annually thereafter). Standardized home BP measurements will be taken every 3\u00a0months with automatic upload to the cloud. Office and ambulatory BP and adverse events will be collected as per routine clinical practice. Quality-of-Life questionnaires will be used to capture patient-reported outcomes.<\/jats:p>\n            <\/jats:sec><jats:sec>\n              <jats:title>Conclusions<\/jats:title>\n              <jats:p>This observational registry will provide real-world information on the safety and effectiveness of uRDN in a large population of patients treated during routine clinical practice, and also allow for a better understanding of responses in prespecified subgroups. The focus on home BP in this registry is expected to improve completeness of long-term follow-up and provide unique insights into BP over time.<\/jats:p>\n            <\/jats:sec><jats:sec>\n              <jats:title>Graphical abstract<\/jats:title>\n              <jats:p>Global Paradise System registry study design. ABP, ambulatory blood pressure; BP, blood pressure; FU, follow-up; M, month; OBP, office blood pressure.<\/jats:p>\n              \n            <\/jats:sec>","DOI":"10.1007\/s00392-023-02325-x","type":"journal-article","created":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T09:02:37Z","timestamp":1699520557000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Real-world experience with ultrasound renal denervation utilizing home blood pressure monitoring: the Global Paradise System registry study design"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4425-549X","authenticated-orcid":false,"given":"Felix","family":"Mahfoud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Azizi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost","family":"Daemen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew S. P.","family":"Sharp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul","family":"Patak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan F.","family":"Iglesias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Kirtane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi D. L.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Scicli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melvin D.","family":"Lobo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,9]]},"reference":[{"key":"2325_CR1","doi-asserted-by":"publisher","unstructured":"NCD Risk Factor Collaboration (NCD-RisC) (2021) Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet 398(10304):957\u2013980. https:\/\/doi.org\/10.1016\/S0140-6736(21)01330-1","DOI":"10.1016\/S0140-6736(21)01330-1"},{"issue":"11","key":"2325_CR2","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/s41569-021-00559-8","volume":"18","author":"B Zhou","year":"2021","unstructured":"Zhou B, Perel P, Mensah GA, Ezzati M (2021) Global epidemiology, health burden and effective interventions for elevated blood pressure and hypertension. Nat Rev Cardiol 18(11):785\u2013802. https:\/\/doi.org\/10.1038\/s41569-021-00559-8","journal-title":"Nat Rev Cardiol"},{"issue":"25","key":"2325_CR3","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","volume":"76","author":"GA Roth","year":"2020","unstructured":"Roth GA, Mensah GA, Johnson CO et al (2020) Global burden of cardiovascular diseases and risk factors, 1990\u20132019: update from the GBD 2019 STUDY. J Am Coll Cardiol 76(25):2982\u20133021. https:\/\/doi.org\/10.1016\/j.jacc.2020.11.010","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"2325_CR4","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1161\/circresaha.118.313220","volume":"124","author":"M Burnier","year":"2019","unstructured":"Burnier M, Egan BM (2019) Adherence in hypertension. Circ Res 124(7):1124\u20131140. https:\/\/doi.org\/10.1161\/circresaha.118.313220","journal-title":"Circ Res"},{"issue":"4","key":"2325_CR5","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1161\/hypertensionaha.118.11308","volume":"72","author":"F Rea","year":"2018","unstructured":"Rea F, Corrao G, Merlino L, Mancia G (2018) Initial antihypertensive treatment strategies and therapeutic inertia. Hypertension 72(4):846\u2013853. https:\/\/doi.org\/10.1161\/hypertensionaha.118.11308","journal-title":"Hypertension"},{"key":"2325_CR6","doi-asserted-by":"publisher","unstructured":"Whelton PK, Carey RM, Aronow WS et al (2018) ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American college of cardiology\/American heart association task force on clinical practice guidelines. Hypertension. https:\/\/doi.org\/10.1161\/HYP.0000000000000065","DOI":"10.1161\/HYP.0000000000000065"},{"issue":"6","key":"2325_CR7","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1161\/hypertensionaha.120.15026","volume":"75","author":"T Unger","year":"2020","unstructured":"Unger T, Borghi C, Charchar F et al (2020) International society of hypertension global hypertension practice guidelines. Hypertension 75(6):1334\u20131357. https:\/\/doi.org\/10.1161\/hypertensionaha.120.15026","journal-title":"Hypertension"},{"issue":"33","key":"2325_CR8","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"39","author":"B Williams","year":"2018","unstructured":"Williams B, Mancia G, Spiering W et al (2018) 2018 ESC\/ESH guidelines for the management of arterial hypertension. Eur Heart J 39(33):3021\u20133104. https:\/\/doi.org\/10.1093\/eurheartj\/ehy339","journal-title":"Eur Heart J"},{"issue":"5","key":"2325_CR9","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.1161\/hyp.0000000000000084","volume":"72","author":"RM Carey","year":"2018","unstructured":"Carey RM, Calhoun DA, Bakris GL et al (2018) Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association. Hypertension 72(5):e53\u2013e90. https:\/\/doi.org\/10.1161\/hyp.0000000000000084","journal-title":"Hypertension"},{"issue":"12","key":"2325_CR10","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/j.jcin.2019.02.050","volume":"12","author":"MA Weber","year":"2019","unstructured":"Weber MA, Mahfoud F, Schmieder RE et al (2019) Renal denervation for treating hypertension: current scientific and clinical evidence. JACC Cardiovasc Interv 12(12):1095\u20131105. https:\/\/doi.org\/10.1016\/j.jcin.2019.02.050","journal-title":"JACC Cardiovasc Interv"},{"issue":"23","key":"2325_CR11","doi-asserted-by":"publisher","first-page":"2614","DOI":"10.1016\/j.jcin.2021.09.020","volume":"14","author":"Y Ahmad","year":"2021","unstructured":"Ahmad Y, Francis DP, Bhatt DL, Howard JP (2021) Renal denervation for hypertension: a systematic review and meta-analysis of randomized, blinded, placebo-controlled trials. JACC Cardiovasc Interv 14(23):2614\u20132624. https:\/\/doi.org\/10.1016\/j.jcin.2021.09.020","journal-title":"JACC Cardiovasc Interv"},{"issue":"24","key":"2325_CR12","doi-asserted-by":"publisher","first-page":"2922","DOI":"10.1016\/j.jcin.2020.09.054","volume":"13","author":"M Azizi","year":"2020","unstructured":"Azizi M, Daemen J, Lobo MD et al (2020) 12-Month results from the unblinded phase of the RADIANCE-HTN SOLO trial of ultrasound renal denervation. JACC Cardiovasc Interv 13(24):2922\u20132933. https:\/\/doi.org\/10.1016\/j.jcin.2020.09.054","journal-title":"JACC Cardiovasc Interv"},{"issue":"10293","key":"2325_CR13","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1016\/S0140-6736(21)00788-1","volume":"397","author":"M Azizi","year":"2021","unstructured":"Azizi M, Sanghvi K, Saxena M et al (2021) Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial. The Lancet 397(10293):2476\u20132486. https:\/\/doi.org\/10.1016\/S0140-6736(21)00788-1","journal-title":"The Lancet"},{"issue":"10137","key":"2325_CR14","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1016\/S0140-6736(18)31082-1","volume":"391","author":"M Azizi","year":"2018","unstructured":"Azizi M, Schmieder RE, Mahfoud F et al (2018) Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. The Lancet 391(10137):2335\u20132345. https:\/\/doi.org\/10.1016\/S0140-6736(18)31082-1","journal-title":"The Lancet"},{"issue":"22","key":"2325_CR15","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1161\/CIRCULATIONAHA.119.040451","volume":"139","author":"M Azizi","year":"2019","unstructured":"Azizi M, Schmieder RE, Mahfoud F et al (2019) Six-month results of treatment-blinded medication titration for hypertension control after randomization to endovascular ultrasound renal denervation or a sham procedure in the RADIANCE-HTN SOLO Trial. Circulation 139(22):2542\u20132553. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.040451","journal-title":"Circulation"},{"issue":"9","key":"2325_CR16","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1097\/HJH.0000000000002120","volume":"37","author":"J Daemen","year":"2019","unstructured":"Daemen J, Mahfoud F, Kuck KH et al (2019) Safety and efficacy of endovascular ultrasound renal denervation in resistant hypertension: 12-month results from the ACHIEVE study. J Hypertens 37(9):1906\u20131912. https:\/\/doi.org\/10.1097\/HJH.0000000000002120","journal-title":"J Hypertens"},{"key":"2325_CR17","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2022.3904","author":"M Azizi","year":"2022","unstructured":"Azizi M, Mahfoud F, Weber MA et al (2022) Effects of renal denervation vs. sham in resistant hypertension after medication escalation: prespecified analysis at 6 months of the RADIANCE-HTN TRIO randomized clinical trial. JAMA Cardiol. https:\/\/doi.org\/10.1001\/jamacardio.2022.3904","journal-title":"JAMA Cardiol"},{"key":"2325_CR18","unstructured":"Kirtane A, Mahfoud F, Sharp A, Fisher N, Azizi M (2022) Patient-level pooled analysis of ultrasound renal denervation in the sham-controlled RADIANCE II, RADIANCE-HTN SOLO and RADIANCE-HTN TRIO Trials. In: American Heart Association scientific sessions"},{"key":"2325_CR19","doi-asserted-by":"publisher","first-page":"191","DOI":"10.2147\/VHRM.S350006","volume":"18","author":"J Topouchian","year":"2022","unstructured":"Topouchian J, Zelveian P, Hakobyan Z, Gharibyan H, Asmar R (2022) Accuracy of the Withings BPM connect device for self-blood pressure measurements in general population\u2014validation according to the association for the advancement of medical instrumentation\/European Society of Hypertension\/International Organization for Standardization Universal Standard. Vasc Health Risk Manag 18:191\u2013200. https:\/\/doi.org\/10.2147\/VHRM.S350006","journal-title":"Vasc Health Risk Manag"},{"issue":"4","key":"2325_CR20","doi-asserted-by":"publisher","first-page":"E42","DOI":"10.1161\/CIR.0000000000000803","volume":"142","author":"D Shimbo","year":"2020","unstructured":"Shimbo D, Artinian NT, Basile JN et al (2020) Self-measured blood pressure monitoring at home: a joint policy statement from the American heart association and American medical association. Circulation 142(4):E42\u2013E63. https:\/\/doi.org\/10.1161\/CIR.0000000000000803","journal-title":"Circulation"},{"issue":"5","key":"2325_CR21","doi-asserted-by":"publisher","first-page":"e35","DOI":"10.1161\/HYP.0000000000000087","volume":"73","author":"P Muntner","year":"2019","unstructured":"Muntner P, Shimbo D, Carey RM et al (2019) Measurement of blood pressure in humans: a scientific statement from the American Heart Association. Hypertension 73(5):e35\u2013e66.\u00a0https:\/\/doi.org\/10.1161\/HYP.0000000000000087","journal-title":"Hypertension"},{"issue":"10285","key":"2325_CR22","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1016\/S0140-6736(21)00590-0","volume":"397","author":"K Rahimi","year":"2021","unstructured":"Rahimi K, Bidel Z, Nazarzadeh M et al (2021) Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. Lancet 397(10285):1625\u20131636. https:\/\/doi.org\/10.1016\/S0140-6736(21)00590-0","journal-title":"Lancet"},{"issue":"8","key":"2325_CR23","doi-asserted-by":"publisher","first-page":"e677","DOI":"10.4244\/EIJ-D-22-00305","volume":"18","author":"F Rader","year":"2022","unstructured":"Rader F, Kirtane AJ, Wang Y et al (2022) Durability of blood pressure reduction after ultrasound renal denervation: three-year follow-up of the treatment arm of the randomised RADIANCE-HTN SOLO trial. EuroIntervention 18(8):e677\u2013e685. https:\/\/doi.org\/10.4244\/EIJ-D-22-00305","journal-title":"EuroIntervention"},{"issue":"11","key":"2325_CR24","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1007\/s00392-022-02064-5","volume":"111","author":"MA Weber","year":"2022","unstructured":"Weber MA, Schmieder RE, Kandzari DE et al (2022) Hypertension urgencies in the SPYRAL HTN-OFF MED Pivotal trial. Clin Res Cardiol 111(11):1269\u20131275. https:\/\/doi.org\/10.1007\/s00392-022-02064-5","journal-title":"Clin Res Cardiol"},{"issue":"16","key":"2325_CR25","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1093\/eurheartj\/ehaa121","volume":"41","author":"F Mahfoud","year":"2020","unstructured":"Mahfoud F, Azizi M, Ewen S et al (2020) Proceedings from the 3rd European Clinical Consensus Conference for clinical trials in device-based hypertension therapies. Eur Heart J 41(16):1588\u20131599. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa121","journal-title":"Eur Heart J"},{"issue":"42","key":"2325_CR26","doi-asserted-by":"publisher","first-page":"3474","DOI":"10.1093\/eurheartj\/ehz118","volume":"40","author":"F Mahfoud","year":"2019","unstructured":"Mahfoud F, B\u00f6hm M, Schmieder R et al (2019) Effects of renal denervation on kidney function and long-term outcomes: 3-year follow-up from the Global SYMPLICITY Registry. Eur Heart J 40(42):3474\u20133482. https:\/\/doi.org\/10.1093\/eurheartj\/ehz118","journal-title":"Eur Heart J"},{"issue":"23","key":"2325_CR27","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1016\/j.jacc.2020.04.036","volume":"75","author":"F Mahfoud","year":"2020","unstructured":"Mahfoud F, Mancia G, Schmieder R et al (2020) Renal denervation in high-risk patients with hypertension. J Am Coll Cardiol 75(23):2879\u20132888. https:\/\/doi.org\/10.1016\/j.jacc.2020.04.036","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"2325_CR28","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1007\/s00392-022-02056-5","volume":"111","author":"VJM Zeijen","year":"2022","unstructured":"Zeijen VJM, Feyz L, Nannan Panday R et al (2022) Long-term follow-up of patients undergoing renal sympathetic denervation. Clin Res Cardiol 111(11):1256\u20131268. https:\/\/doi.org\/10.1007\/s00392-022-02056-5","journal-title":"Clin Res Cardiol"},{"issue":"1","key":"2325_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40292-021-00492-4","volume":"29","author":"B Citoni","year":"2022","unstructured":"Citoni B, Figliuzzi I, Presta V, Volpe M, Tocci G (2022) Home blood pressure and telemedicine: a modern approach for managing hypertension during and after COVID-19 pandemic. High Blood Press Cardiovasc Prev 29(1):1\u201314. https:\/\/doi.org\/10.1007\/s40292-021-00492-4","journal-title":"High Blood Press Cardiovasc Prev"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-023-02325-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00392-023-02325-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-023-02325-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T09:04:28Z","timestamp":1699520668000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00392-023-02325-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,9]]},"references-count":29,"alternative-id":["2325"],"URL":"https:\/\/doi.org\/10.1007\/s00392-023-02325-x","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,9]]},"assertion":[{"value":"25 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"FM is supported by Deutsche Gesellschaft f\u00fcr Kardiologie (DGK), Deutsche Forschungsgemeinschaft (SFB TRR219, Project-ID 322900939), and Deutsche Herzstiftung. He has received scientific support from Ablative Solutions, Medtronic and Recor Medical and speaker honoraria\/consulting fees from Ablative Solutions, Amgen, Astra-Zeneca, Bayer, Boehringer Ingelheim, Inari, Medtronic, Merck, Recor Medical, Servier, and Terumo. MA has received research grants from the European Horizon 2020 program; has received grant support and nonfinancial support from Recor Medical, Idorsia, Novartis; and has received personal fees from Alnylam Pharmaceuticals,\u00a0Cincor, Medtronic, Astra-Zeneca, and Novartis. JD has\u00a0received institutional grant\/research support from Abbott Vascular, Boston Scientific, ACIST Medical, Medtronic, Microport, Pie Medical, and Recor Medical, and consultancy and speaker fees from Abbott Vascular, Abiomed, ACIST Medical, Boston Scientific, Cardialysis BV, CardiacBooster, Kaminari Medical, Recor  Medical, PulseCath, Pie Medical, Sanofi, Siemens Health Care and Medtronic. ASharp has received personal fees from Recor Medical, Medtronic, Boston Scientific, Penumbra and Philips. AP has received institutional grant\/research support, consultancy\/speaker fees and travel grants from Recor Medical, Medtronic, and Ablative Solutions. JFI has received research grants to the institution from Abbott Vascular, Astra Zeneca, Biosensors International, Biotronik, Concept Medical, Philips Volcano, and Terumo Corp.; honoraria\/speaker\u2019s fees from Astra Zeneca, Biosensors International, Biotronik, Bristol Myers Squibb\/Pfizer, Cordis, Concept Medical, Medalliance, Medtronic, Novartis, Philips Volcano, and Terumo Corp.; and is consultant for Biotronik, Cordis, Medtronic, Recor Medical, and Terumo Corp. AK reports Institutional funding to Columbia University and\/or Cardiovascular Research Foundation from Medtronic, Boston Scientific, Abbott Vascular,\u00a0Abiomed,  CSI, CathWorks,\u00a0Siemens, Philips, Recor Medical.  In addition to research grants, institutional funding includes fees paid to Columbia University and\/or Cardiovascular Research Foundation for speaking engagements\u00a0and\/or consulting. Personal: Consulting: Neurotronic;\u00a0Travel Expenses\/Meals from Medtronic, Boston Scientific, Abbott Vascular, Abiomed, CSI, CathWorks, Siemens, Philips, Recor Medical, Chiesi, OpSens, Zoll, and Regeneron. NF has received grant support and personal fees from Recor Medical, and personal fees from Medtronic. AScicli is an employee of Recor Medical. MLB is a consultant to Medtronic, Recor Medical, Ablative Solutions and Vascular Dynamics and has received educational grant funding from Medtronic and Recor Medical.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}